

**To:** [redacted] <[redacted]@rivm.nl>  
**Cc:** [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>  
**From:** [redacted] <[redacted]@rivm.nl>  
**Sent:** Tue 2/23/2021 7:46:38 PM  
**Subject:** RE: Twijfels bij zorgmedewerkers  
**Received:** Tue 2/23/2021 7:46:39 PM

Dank je wel voor je terugkoppeling [redacted] in NL ging in eerste instantie ook de discussie over mRNA of niet, maar dat lijkt inmiddels al weer passe. Blijft een uitdaging om zowel health care workers als 'gewone' mensen het zich te laten vaccineren door het vaccin dat ze aangeboden krijgen. Mensen krijgen geen keuze, ook niet als ze een bepaald vaccin weigeren. Fijn als jullie met het literatuurteam hier oog voor kunnen houden, want dit gaat komende tijd alleen nog maar meer spelen.

Ik cc meteen maar de gedragsunit collega's in die zich (o.a.) bezig houden met vaccinatiedeelname.

Groet,

**From:** [redacted] <[redacted]@rivm.nl>

**Sent:** dinsdag 23 februari 2021 18:17

**To:** [redacted] <[redacted]@rivm.nl>

**Subject:** Twijfels bij zorgmedewerkers

Hi

Je vraag over twijfels bij zorgmedewerkers afhankelijk van vaccin heb ik voorgelegd aan [redacted] tijdens deze besloten bijeenkomst (afspraak is eigenlijk dat we niets delen): Behavioral Science and Covid-19 Vaccine Acceptance: A Conversation (Part II)  
 Tuesday, February 23rd at 11:00 AM EST

Ze zei eerst:

there are several studies of HCW intentions, though most prior to much knowledge of specific vaccines. This one I administered in December (<https://www.medrxiv.org/content/10.1101/2020.12.19.20248555v1>) is in press at JAMA Network Open and cites some others. We will also soon post a preprint with results of an email campaign to nudge reluctant HCWs to schedule their vaccine appointments. HCWs were randomized to either a social proof or "reframing risk" email. Both led to increased appointments compared to a delayed no-contact control group (OR = 5.65/5.70, 95% CI [~3.9, ~8.1], p < .001) but the difference between the emails wasn't statistically significant.

Toen vroeg ik: heb je inzicht in bereidheid afhankelijk van vaccins?

Ze zei:

We didn't study this directly, but "it depends which vaccine I'm offered" was one response for those who said they were hesitant. We qualitatively coded "other" reasons for hesitancy given in free response and those who said they had concerns about mRNA vaccines were added to the "depends which vaccine I get" group. A total of 11.4% of those who said they were hesitant identified this as among the reason(s) for their hesitancy. In the U.S. in Dec., only the two mRNA vaccines were on the clear horizon (or authorized during data collection), but others, especially J&J's, were in the news. But check out this preprint that specifically focuses on Saudi Arabian HCW preferences among the 7 vaccines that have completed Phase 3 trials. Pfizer does well, comparatively.  
<https://www.medrxiv.org/content/10.1101/2020.12.22.20248657v1.full>

Groeten,

**Dr.** [redacted]

**National Institute for Public Health & the Environment (RIVM)**  
 Department of Health Economics

Antonie van Leeuwenhoeklaan 9  
3721 MA Bilthoven

5.1.2e